SCHEMBL323374

SCHEMBL323374

Nc1cc(N)c2ccccc2n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 10/20 0.64
BACE1 P56817 2/20 0.64
ACHE P22303 2/20 0.62
KDM4E B2RXH2 3/20 0.54
ALDH1A1 P00352 3/20 0.54
GLA P06280 3/20 0.54
HPGD P15428 3/20 0.54
CASP1 P29466 2/20 0.54
CASP7 P55210 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
HSD17B10 Q99714 2/20 0.54
CHRM2 P08172 1/20 0.54
ADRA2A P08913 1/20 0.54
ADORA3 P0DMS8 1/20 0.54
CHRM1 P11229 1/20 0.54
NQO2 P16083 1/20 0.54
MAOA P21397 1/20 0.54
DRD1 P21728 1/20 0.54
SLC6A2 P23975 1/20 0.54
ADRA1A P35348 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29690490 1.00 NCF1 (0.64) NCF1BACE1ACHEKDM4EALDH1A1
Trifluoroacetic Acid SCHEMBL27826163 0.84 BACE1 (0.57) NCF1BACE1ACHEKDM4EALDH1A1
SCHEMBL28159979 0.82 BACE1 (0.58) NCF1BACE1ACHEKDM4EALDH1A1
SCHEMBL28107175 0.80 NCF1 (0.46) NCF1BACE1ACHEKDM4EALDH1A1
SCHEMBL1848398 0.78 NCF1 (0.60) NCF1BACE1ACHEKDM4EALDH1A1
SCHEMBL1845376 0.78 NCF1 (0.60) NCF1BACE1ACHEKDM4EALDH1A1
SCHEMBL482375 0.78 BACE1 (0.60) NCF1BACE1ACHEKDM4EALDH1A1
SCHEMBL1845788 0.78 NCF1 (0.60) NCF1BACE1ACHEKDM4EALDH1A1
SCHEMBL3094768 0.78 BACE1 (1.00) NCF1BACE1ACHEKDM4EALDH1A1
SCHEMBL31667822 0.78 BACE1 (0.60) NCF1BACE1ACHEKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110449178-B Photocatalyst, preparation method and application thereof 广州大学 2022-05-24 CN claimed
CN-110449178-A A kind of photochemical catalyst, preparation method and its application UNIV GUANGZHOU 2019-11-15 CN claimed
CN-109641886-A bicyclic BET bromodomain inhibitors and uses thereof 康威基内有限公司 2019-04-16 CN claimed
EP-3220912-A1 TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS Pharmacyclics LLC (US) 2017-09-27 EP claimed
CN-107207463-A Quinoline derivatives for the treatment of inflammatory diseases ABIVAX公司 2017-09-26 CN claimed
WO-2016081460-A1 TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS PHARMACYCLICS LLC (US) 2016-05-26 WO claimed
CN-101056877-B Imidazoquinoline compounds NOVARTIS VACCINES & DIAGNOSTIC 2010-06-09 CN claimed
CN-101056877-A Imidazoquinoline compounds NOVARTIS VACCINES & DIAGNOSTIC (US) 2007-10-17 CN claimed
EP-1797091-A2 IMIDAZOQUINOLINE COMPOUNDS Novartis Vaccines and Diagnostics, Inc. (US) 2007-06-20 EP claimed
WO-2006031878-A2 IMIDAZOQUINOLINE COMPOUNDS NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2006-03-23 WO claimed
WO-2024074559-A1 COMBINATION OF SUBSTITUTED 2,4 DIAMINO-QUINOLINE COMPOUNDS AND MEK INHIBITORS FOR USE IN THE TREATMENT OF LIVER CANCERS GENOSCIENCE PHARMA (FR) 2024-04-11 WO disclosed
US-20230348574-A1 RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-11-02 US disclosed
EP-4218799-A1 RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME GlaxoSmithKline Biologicals S.A. (BE) 2023-08-02 EP disclosed
EP-4218800-A1 RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME GlaxoSmithKline Biologicals S.A. (BE) 2023-08-02 EP disclosed
CN-113845548-B Platinum complex of quinazoline hydrazine dithioformate and preparation method and application thereof 深圳大学 2023-06-06 CN disclosed
EP-0175641-B1 PROCESS FOR THE PREPARATION OF DIMETHYLMALEIC ANHYDRIDE CIBA-GEIGY AG (CH) 1988-02-24 EP disclosed
US-4644069-A HEATING MALEIC ACID OR ANHYDRIDE WITH AN AMIDINE OR ITS SALT CIBA-GEIGY CORPORATION (US) 1987-02-17 US disclosed
US-4639531-A HETEROCYCLIC AMIDINE CATALYST CIBA-GEIGY CORPORATION (US) 1987-01-27 US disclosed
EP-0175641-A1 Process for the preparation of dimethylmaleic anhydride CIBA-GEIGY AG (CH) 1986-03-26 EP disclosed
EP-0174272-A1 Process for the preparation of dimethylmaleic anhydride CIBA-GEIGY AG (CH) 1986-03-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348574-A1 RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME RNASEL, TIMCC, RNGTT NCF1 554/4885BACE1 2485/4885ACHE 4528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.